This business information is not released now.


Back
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.


MEDRx Co., Ltd
【Field/Business】
Pharmaceutical/Drug Discovery


last update:2017/5/8
Profile

Delegates :
Yonehiro Matsumura


Incorporated :
January  15 , 2002

Paid in Capital :
5101 Million yen  Listed on Tokyo Stock Exchange (Mothers) since February 2013

Employees :
23 人

Address :
431-7 Nishiyama Higashikagawa-city, Kagawa, Japan KAGAWA
〒769-2712

TEL/FAX :
+81-879-23-3071 / +81-879-23-3072

URL:
http://www.medrx.co.jp/english/index.html

Attachment :

Mission/Background :
MEDRx is a pharmaceutical venture company capitalizing on unique transdermal technologies.
ILTS(R) : Ionic Liquid Transdermal System
NCTS(R) : Nano-sized Colloid Transdermal System
AMRTS : Abuse and Misuse Resistant Transdermal System
KENZAN : Micro Needle Array

Technology & Business
Ionic liquid transdermal system (ILTS(R)) technology enables to aquire adequate solbility of various APIs through:
- Forming ionic liqid with the API, or
- Solving the API in ionic liquid.
MEDRx is the world first company to accomplish the dramatically increased penetration capability of drugs by ILTS(R). We are also the only company to have run clinical trials on the efficacy of API-IL (Rogers RD, et.al. Ionic liquids in drug delivery. Expt Opin. Drug Deliv. 2013; 10: 1367-81).
ILTS(R) technology represents:
1. Ionic liquid library consisted of the combinations of proven compounds to apply on the human bodies safely.
2. Know-how to select preferable ionic liquids for the drug to increase the penetration capability.
3. Know-how to transform ionic liquids with drugs into the preferable formulations, such as patches and ointments, for the administration.
ILTS(R) patent portfolios cover preparations for wide range of APIs.
Products & Service
Products & Service Name
Stage
Outline
Milestone
MRX-4TZT, Tizanidine transdermal patch for the management of Spasticity
Phase1
Signed a worldwide licensing agreement (except for East Asia) with Cipla USA
NDA approval in US
MRX-5LBT
Phase1
Lidocaine topical patch for PHN
NDA approval in US
MRX-1OXT
Preclinical
Oxycodone transdermal patch for the chronic pain management
Start of phase 1 study in US








Highlights
In October 2016,
Joint presentation by MEDRx and Kitasato Daiichi Sankyo Vaccine at the 20th Annual Meeting of the Japanese Society for Vaccinology
"Examination of mouse immunogenicity using transdermal influenza hemagglutinin (HA) vaccine administered using microneedles"

In April 2017,
MEDRx has signed a worldwide licensing agreement (except for East Asia) with Cipla USA Inc. to further develop and commercialize MRX-4TZT, a Tizanidine patch for the management of Spasticity.
Hot news

Alliance strategy
We are now seeking partners who are willing to in-license MRX-5LBT (lidocaine patch) or MRX-1OXT (oxycodone patch) to feed pipeline.

We are also seeking for counterparts who are willing to in-license the ILTS(R) / NCTS(R) technology and/or to collaborate in developing a novel transdermal formulation.

We are also seeking for collaboration partners regarding Micro Needle Array.


 
This page is displayed by "Spiral" of PIPED BITS Co.,Ltd., which is a database management ASP service, our contracted partner.